Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

MKSAP: 82-year-old woman with Alzheimer’s disease

mksap
Conditions
December 15, 2018
Share
Tweet
Share

Test your medicine knowledge with the MKSAP challenge, in partnership with the American College of Physicians.

An 82-year-old woman is seen for follow-up evaluation of Alzheimer disease. Since her last visit 12 weeks ago, she has been taking rivastigmine, with a progressively titrated dosage. The patient’s only new symptoms are increasing insomnia, loss of appetite, and occasional diarrhea; she has had no feelings of hopelessness, helplessness, sadness, or guilt. Her only other medication is hydrochlorothiazide for hypertension.

On physical examination, vital signs are normal. The patient has lost 6.8 kg (15.0 lb) since her last visit. She scores 20/30 on a Mini–Mental State Examination, losing points in the recall, orientation to time, complex commands, and attention and calculation sections; her score 12 weeks ago was 21/30. All other findings from the general physical and neurologic examinations are normal.

Results of laboratory studies, including a complete blood count, comprehensive metabolic profile, and thyroid function tests, are normal.

Which of the following is the most appropriate next step in management?

A. Add donepezil
B. Add memantine
C. Add mirtazapine at bedtime
D. Discontinue rivastigmine

MKSAP Answer and Critique

The correct answer is D. Discontinue rivastigmine.

This patient should stop taking rivastigmine. Given the results of her cognitive testing, she meets criteria for Alzheimer disease of mild severity. She began taking oral rivastigmine, a cholinesterase inhibitor, 12 weeks ago. All of the available cholinesterase inhibitors are approved for mild to moderate Alzheimer disease, except donepezil, which is also approved for the severe stage. Studies of cholinesterase inhibitors and memantine show consistent improvement on measures of cognition and global assessment of dementia, but the effect size is modest and evidence that they improve long-term outcome is lacking. In practice, individual response is variable. There is insufficient evidence to support one cholinesterase inhibitor over another, and choice of treatment in a patient should be based on cost, tolerability, and ease of using the specific formulation. There is also insufficient evidence of the optimal duration of treatment or when therapy should be discontinued. Medication decisions should be made on an individual basis. Cholinesterase inhibitors should be used with caution in patients with cardiac conduction abnormalities, active peptic ulcer disease (because of the risk of bleeding), and seizures. Gastrointestinal adverse effects are common to all cholinesterase inhibitors and include loss of appetite, weight loss, nausea, vomiting, and diarrhea. Insomnia also can occur. This patient has had a significant amount of weight loss, loss of appetite, and insomnia since starting rivastigmine. The most appropriate next step in management would be to discontinue the medication. A trial of a different type of cholinesterase inhibitor could be considered, but only after symptoms subside.

Donepezil, another cholinesterase inhibitor, might be considered as an alternative therapy for this patient. However, no indication supports prescribing multiple cholinesterase inhibitors concomitantly, and rivastigmine should be discontinued as the first step.

Memantine is a noncompetitive N-Methyl-D-aspartate receptor antagonist approved by the FDA for the treatment of moderate to severe Alzheimer disease. Although this drug could be added in the future, this patient’s present symptoms should be addressed first.

Mirtazapine is a nonselective α2-adrenoceptor antagonist effective in the treatment of depression. Stimulation of appetite, weight gain, and somnolence are frequently associated effects, and thus this medication may be the preferred treatment for depressed patients with Alzheimer disease who have insomnia or loss of appetite. This patient has apathy and loss of interest, which are common symptoms in Alzheimer disease, but lacks additional symptoms to suggest depression.

Key Point

  • Gastrointestinal adverse effects can occur with cholinesterase inhibitor therapy.

This content is excerpted from MKSAP 17 with permission from the American College of Physicians (ACP). Use is restricted in the same manner as that defined in the MKSAP 17 Digital license agreement. This material should never be used as a substitute for clinical judgment and does not represent an official position of ACP. All content is licensed to KevinMD.com on an “AS IS” basis without any warranty of any nature. The publisher, ACP, shall not be liable for any damage or loss of any kind arising out of or resulting from use of content, regardless of whether such liability is based in tort, contract or otherwise.

Prev

Primary care today: There are several concerning trends

December 14, 2018 Kevin 20
…
Next

6 ways to ensure you're not accepting a terrible health care job

December 15, 2018 Kevin 0
…

ADVERTISEMENT

Tagged as: Neurology

Post navigation

< Previous Post
Primary care today: There are several concerning trends
Next Post >
6 ways to ensure you're not accepting a terrible health care job

ADVERTISEMENT

More by mksap

  • a desk with keyboard and ipad with the kevinmd logo

    MKSAP: 26-year-old man with back pain

    mksap
  • a desk with keyboard and ipad with the kevinmd logo

    MKSAP: 36-year-old man with abdominal cramping, diarrhea, malaise, and nausea

    mksap
  • a desk with keyboard and ipad with the kevinmd logo

    MKSAP: 52-year-old woman with osteoarthritis of the right hip

    mksap

Related Posts

  • a desk with keyboard and ipad with the kevinmd logo

    MKSAP: 35-year-old woman with constipation

    mksap
  • a desk with keyboard and ipad with the kevinmd logo

    MKSAP: 60-year-old woman with persistent constipation

    mksap
  • a desk with keyboard and ipad with the kevinmd logo

    MKSAP: 45-year-old woman with type 2 diabetes mellitus

    mksap
  • Should only infectious disease specialists be allowed to prescribe antibiotics?

    Craig Bowron, MD
  • The culture of perfection in medicine is a disease

    Andy Cruz, MD
  • 3 ways we’ve failed woman who breastfeed

    Joanna Buscemi, PhD

More in Conditions

  • Why doctors must stop ignoring unintentional weight loss in patients with obesity

    Samantha Malley, FNP-C
  • Why hospitals are quietly capping top doctors’ pay

    Dennis Hursh, Esq
  • Why point-of-care ultrasound belongs in emergency department triage

    Resa E. Lewiss, MD and Courtney M. Smalley, MD
  • Why PSA levels alone shouldn’t define your prostate cancer risk

    Martina Ambardjieva, MD, PhD
  • Reframing chronic pain and dignity: What a pain clinic teaches us about MAiD and chronic suffering

    Olumuyiwa Bamgbade, MD
  • America’s ER crisis: Why the system is collapsing from within

    Kristen Cline, BSN, RN
  • Most Popular

  • Past Week

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • Why timing, not surgery, determines patient survival

      Michael Karch, MD | Conditions
    • Why health care leaders fail at execution—and how to fix it

      Dave Cummings, RN | Policy
    • How digital tools are reshaping the doctor-patient relationship

      Vineet Vishwanath | Tech
  • Past 6 Months

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • The hidden health risks in the One Big Beautiful Bill Act

      Trevor Lyford, MPH | Policy
  • Recent Posts

    • Why ADHD in women requires a new approach [PODCAST]

      The Podcast by KevinMD | Podcast
    • AI is already replacing doctors—just not how you think

      Bhargav Raman, MD, MBA | Tech
    • Why doctors must stop ignoring unintentional weight loss in patients with obesity

      Samantha Malley, FNP-C | Conditions
    • Why more doctors are choosing direct care over traditional health care

      Grace Torres-Hodges, DPM, MBA | Physician
    • Why hospitals are quietly capping top doctors’ pay

      Dennis Hursh, Esq | Conditions
    • Why point-of-care ultrasound belongs in emergency department triage

      Resa E. Lewiss, MD and Courtney M. Smalley, MD | Conditions

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 1 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

  • Most Popular

  • Past Week

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • Why timing, not surgery, determines patient survival

      Michael Karch, MD | Conditions
    • Why health care leaders fail at execution—and how to fix it

      Dave Cummings, RN | Policy
    • How digital tools are reshaping the doctor-patient relationship

      Vineet Vishwanath | Tech
  • Past 6 Months

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • The hidden health risks in the One Big Beautiful Bill Act

      Trevor Lyford, MPH | Policy
  • Recent Posts

    • Why ADHD in women requires a new approach [PODCAST]

      The Podcast by KevinMD | Podcast
    • AI is already replacing doctors—just not how you think

      Bhargav Raman, MD, MBA | Tech
    • Why doctors must stop ignoring unintentional weight loss in patients with obesity

      Samantha Malley, FNP-C | Conditions
    • Why more doctors are choosing direct care over traditional health care

      Grace Torres-Hodges, DPM, MBA | Physician
    • Why hospitals are quietly capping top doctors’ pay

      Dennis Hursh, Esq | Conditions
    • Why point-of-care ultrasound belongs in emergency department triage

      Resa E. Lewiss, MD and Courtney M. Smalley, MD | Conditions

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

MKSAP: 82-year-old woman with Alzheimer’s disease
1 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...